Risedronate Sodium Tablet, Film Coated
Product Images NDC 47335-666

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Risedronate Sodium (NDC 47335-666). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sun Pharmaceutical Industries, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Risedronate-sodium-figure1 (Risedronate Sodium Figure1)

A bar chart comparing the percentage of patients with fractures at various body sites between placebo and risedronate sodium 5 mg groups. Sites include all fractures combined, wrist, humerus, hip, pelvis, leg, and clavicle, with bars representing percentage values for each treatment group.*

FDA Label Image

Risedronate-sodium-figure2 (Risedronate Sodium Figure2)

A bar graph comparing mean percentage change in Bone Mineral Density (BMD) with standard error for placebo and risedronate sodium 5 mg groups at three anatomical sites: Lumbar Spine, Femoral Neck, and Femoral Trochanter. The data show positive BMD changes for the risedronate sodium 5 mg group and negative changes for placebo at all sites.*

FDA Label Image

Risedronate-sodium-figure3 (Risedronate Sodium Figure3)

Bar graph comparing mean percent change in bone mineral density (BMD) with standard error for placebo versus risedronate sodium 5 mg at three anatomical sites: lumbar spine, femoral neck, and femoral trochanter. Each group includes sample sizes ranging from 52 to 60.*

FDA Label Image

Risedronate-sodium-figure4 (Risedronate Sodium Figure4)

A bar chart comparing mean percent change in bone mineral density (BMD) with standard error at three anatomical sites—Lumbar Spine, Femoral Neck, and Femoral Trochanter—between placebo and risedronate sodium 5 mg groups. Sample sizes for each group at each site are indicated.*

FDA Label Image

Risedronate-sodium-figure5 (Risedronate Sodium Figure5)

Bar chart showing the incidence percentage comparing placebo and risedronate sodium 5 mg among patients continuing glucocorticoid treatment, patients initiating glucocorticoid treatment, and the combined groups. Patient counts are noted for each category.*

FDA Label Image

Risedronate-sodium-figure6 (Risedronate Sodium Figure6)

A line graph comparing the percentage change over visit days for Etidronate Disodium 400 mg and Risedronate Sodium 30 mg. The x-axis represents visit days from 0 to 600, divided into treatment, follow-up, and extended follow-up periods. The y-axis shows percentage change, with data points and error bars for each time point and sample size (n) indicated.*

FDA Label Image

Risedronate-sodium-structure (Risedronate Sodium Structure)

Chemical structure diagram of risedronate sodium with molecular weight information. The structure includes phosphate groups and a pyridine ring, indicating the presence of 2.5 molecules of water (hemipentahydrate). Molecular weights for anhydrous and hemi-pentahydrate forms are noted as 305.10 and 350.13 respectively.*

FDA Label Image

Spl-risedronate-150mg (Spl Risedronate 150mg)

Packaging label for Risedronate Sodium Tablet, USP 150 mg, once-a-month oral film-coated tablet by Sun Pharmaceutical Industries, Inc. The label includes dosage instructions, storage conditions, and a diagram illustrating proper intake with water and precautions. The carton specifies Rx only, one-month supply of 1 tablet with NDC 47335-928-60.*

FDA Label Image

Spl-risedronate-30mg (Spl Risedronate 30mg)

Label for Risedronate Sodium Tablets, USP 30 mg, oral film-coated tablets, packaged as 30 tablets per bottle. Distributed by Sun Pharmaceutical Industries, Inc. and manufactured by Sun Pharmaceutical Industries Ltd. The label includes dosage details, storage instructions, barcode, and a note to dispense with the Medication Guide.*

FDA Label Image

Spl-risedronate-35mg (Spl Risedronate 35mg)

Packaging label for Risedronate Sodium Tablets USP, 35 mg, oral film-coated tablets supplied by Sun Pharmaceutical Industries, Inc. The carton states a once-a-week regimen with a 4-week supply of 4 tablets. Instructions on the label advise taking the tablet on a consistent day weekly with water before food or drink, and avoiding lying down or taking other meds for 30 minutes. Manufactured by Sun Pharmaceutical Industries Limited, India, and distributed by Sun Pharmaceutical Industries, Inc., Cranbury, NJ.*

FDA Label Image

Spl-risedronate-5mg (Spl Risedronate 5mg)

Risedronate Sodium Tablets, USP 5 mg film-coated tablets, labeled for oral use, with a package count of 30 tablets. The label shows it is a prescription drug distributed by Sun Pharmaceutical Industries, Inc., and manufactured by Sun Pharmaceutical Industries Ltd. The label includes storage instructions, dosage information prompt, and a barcode.*

FDA Label Image

Spl-risedronate-75mg (Spl Risedronate 75mg)

Packaging label for Risedronate Sodium Tablets, USP 75 mg, film-coated oral tablets in a two consecutive days-a-month, one-month pack containing 2 tablets. Label includes usage instructions, dosage information, storage conditions, and the Sun Pharmaceutical Industries, Inc. logo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.